This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

The HIV/HBV/HCV test kits market plays a vital role in the global fight against infectious diseases. These diagnostic tools are crucial for early detection and effective treatment of HIV, hepatitis B ...

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea ...

Less than three years after Sovaldi’s launch, hepatitis C (hep ... make HCV screening more routine is getting underway. Gilead says 14 million people in the US were screened for the virus ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

ASPPH proudly joined public health and medical leaders for a Congressional Briefing on the Hepatitis C Elimination Imperative ...